PMID- 32823395
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20231112
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 68
IP  - 9
DP  - 2020 Sep
TI  - Human immunodeficiency virus and intraocular inflammation in the era of highly 
      active anti retroviral therapy - An update.
PG  - 1787-1798
LID - 10.4103/ijo.IJO_1248_20 [doi]
AB  - Intraocular inflammation in patients with human immunodeficiency virus (HIV) 
      infection is commonly due to infectious uveitis. Ocular lesions due to 
      opportunistic infections (OI) are the most common and have been described 
      extensively in the pre highly active antiretroviral therapy (HAART) era. Many eye 
      lesions were classified as acquired immunodeficiency syndrome (AIDS) defining 
      illnesses. HAART-associated improvement in immunity of the individual has changed 
      the pattern of incidence of these hitherto reported known lesions leading to a 
      marked reduction in the occurrence of ocular OI. Newer ocular lesions and newer 
      ocular manifestations of known agents have been noted. Immune recovery uveitis 
      (IRU), the new menace, which occurs as part of immune recovery inflammatory 
      syndrome (IRIS) in the eye, can present with significant ocular inflammation and 
      can pose a diagnostic and therapeutic challenge. Balancing the treatment of 
      inflammation with the risk of reactivation of OI is a task by itself. Ocular 
      involvement in the HAART era can be due to the adverse effects of some systemic 
      drugs used in the management of HIV/AIDS. Drug-associated retinal toxicity and 
      other ocular side effects are being increasingly reported. In this review, we 
      discuss the ocular manifestations in HIV patients and its varied presentations 
      following the introduction of HAART, drug-associated lesions, and the current 
      treatment guidelines.
FAU - Sudharshan, Sridharan
AU  - Sudharshan S
AD  - Department of Uveitis, Medical Research Foundation, Chennai, Tamil Nadu, India.
FAU - Nair, Nivedita
AU  - Nair N
AD  - Department of Uveitis, Medical Research Foundation, Chennai, Tamil Nadu, India.
FAU - Curi, Andre
AU  - Curi A
AD  - Andre Luiz Land Curi, National Institute of Infectious Diseases - INI/ Fiocruz; 
      Clinical Research Laboratory of Infectious, Diseases in Ophthalmology - INI / 
      Fiocruz, Brazil.
FAU - Banker, Alay
AU  - Banker A
AD  - Banker's Retina Clinic and Laser Centre, Ahmedabad, Gujarat, India.
FAU - Kempen, John H
AU  - Kempen JH
AD  - Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical 
      School; Schepens Eye Research Institute, Boston, Massachusetts, USA; MCM Eye 
      Unit, MyungSung Christian Medical Center (MCM) General Hospital and MyungSung 
      Medical College, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
SB  - IM
MH  - *AIDS-Related Opportunistic Infections/drug therapy
MH  - Antiretroviral Therapy, Highly Active/adverse effects
MH  - *Cytomegalovirus Retinitis
MH  - HIV
MH  - *HIV Infections/complications/drug therapy
MH  - Humans
MH  - Inflammation/drug therapy
MH  - *Uveitis/diagnosis/drug therapy
PMC - PMC7690468
OTO - NOTNLM
OT  - AIDS
OT  - CMV retinitis
OT  - HAART
OT  - HIV
OT  - IRU
OT  - drug-induced uveitis
OT  - herpes zoster
OT  - intraocular inflammation
OT  - ocular TB
OT  - ocular opportunistic infections
OT  - ocular syphilis
OT  - ocular toxoplasmosis
OT  - retinopathy
OT  - uveitis
COIS- None
EDAT- 2020/08/23 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/09/01
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - IndianJOphthalmol_2020_68_9_1787_292514 [pii]
AID - IJO-68-1787 [pii]
AID - 10.4103/ijo.IJO_1248_20 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2020 Sep;68(9):1787-1798. doi: 10.4103/ijo.IJO_1248_20.